Videos

Tivozanib Tolerability Shows Potential Advantage for Patients with Advanced RCC

May 20, 2020

Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.